Expression of CD1d on tumor cells was confirmed in the majority of MM, (myelo)monocytic AML, and CLL patients, and the CD1d-Vδ2 bsTCE-mediated engagement of type 1 NKT and Vγ9Vδ2-T cells resulting in a Th1 cytokine response and robust tumor cell lysis was also observed using patient-derived tumor samples. The gene discussed is CD1D; the disease is acute myeloid leukemia.